It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
A study by the Population Council (Begay 2011) has found that every one of a panel of 41 commercially-available sexual lubricants for sale in the USA damaged human rectal and colonic cells in the test tube and compromised the integrity of the single-cell layer that forms the surface of the rectum. In contrast Carraguard, a gel formerly tried as an experimental microbicide, did not damage cells Unexpectedly, the investigators found that four of the lubricants not only damaged the rectal lining cells but appeared actively to increase HIV replication in the cell cultures. They found that this activity was caused by polyquaternium-15, a commonly-used cosmetic ingredient, which has the property of facilitating HIV’s attachment to cells.
The Council has a current product pipeline that includes next-generation gels based on carrageenan as well as other natural and man-made polymers that contain one or more active pharmaceutical ingredients and can be used independently of coitus as well as rings that remain in place for 1–6 months for long-acting delivery of anti-HIV compounds in the vagina.
Im gonna take a shot in the dark here, maybe its because things dont belong in your butt?
Originally posted by FrancoUn-American
By 2011 I'm pretty sure people are quite aware of HIV/AIDS.
"Where ignorance is bliss, 'tis folly to be wise." - Thomas Gray (1716 - 1771)
“If knowledge can create problems, it is not through ignorance that we can solve them.” - Isaak Yudovich Ozimov (aka Isaac Asimov) - (1920 - 1992)
“Our knowledge can only be finite, while our ignorance must necessarily be infinite.” - Sir Karl Raimund Popper (1902 - 1994)
“One of the sanest, surest, and most generous joys of life comes from being happy over the good fortune of others.” - Robert Anson Heinlein (1907 - 1988)
Microbicides -- substances applied topically on the inside of the rectum or vagina -- could potentially help prevent the rectal transmission of HIV, and some are being tested in early Phase I safety studies. Another approach called oral pre-exposure prophylaxis (PrEP) involves the use of antiretroviral drugs to reduce the risk of HIV in HIV-negative people. A large Phase III trial of PrEP involving men who have sex with men in South America, Africa and the United States is expected to report results by early next year. Yet, if either of these approaches is found effective in clinical trials, they will do no good if those most at risk don't use them. Other research presented at the conference sheds light on this issue. Summaries of all three studies are provided below.